Podium to Practice: ESMO® 2025 – GI: FORTITUDE-101
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
LBA10 – Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase 3 study results
This program has been made possible through unrestricted support from Amgen.
Studies/trials discussed:
LBA10 – Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase 3 study results
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.